BSR: Patient selection key to using rituximab in lupus

MANCHESTER, U.K. – Although around half of patients with refractory systemic lupus erythematous (SLE) benefit from rituximab treatment at 6 months, there is a subgroup of patients that appears to do worse, according to research presented at the British Society for Rheumatology annual...
Source: Skin and Allergy News - Category: Dermatology Tags: CME-candidate RHEUM Conference News FPN Conferences IMN Conferences SAN Conference News FPN News FPN Rheumatology RHEUM News Source Type: news